Patient Rating:

4.8 out of 5

67 Patient Ratings
64 Patient Comments

Michael W. Deininger, M.D., Ph.D.

Division Chief, Division of Hematology and Hematologic Malignancies

Patient Rating:

4.8 out of 5

67 Patient Ratings
64 Patient Comments

Specialties

Languages

  • English
  • German
  • Russian

Clinical Details

Phone Number Clinical Office Address
(801) 587-4630
Huntsman Cancer Hospital
Clinic 2C/BMT, Hematology-Benign
1950 Circle of Hope
Salt Lake City, UT 84112
Map
(801) 585-6906
Huntsman Cancer Hospital
Clinic 2C/BMT, Hematology-Malignant
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Specialties

Bio

Michael Deininger, MD, PhD, is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He has extensive experience treating patients with blood cancers. He has a particular interest in chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia. He sees patients at the University of Utah Huntsman Cancer Institute, Clinic 2B.

For questions regarding Dr. Deininger's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Oncological Sciences - Adjunct Professor
Academic Divisions Hematology/BMT
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.8
My confidence in care provider
4.8
Time care provider spent with me
4.7
Care provider spoke using clear language
4.8
Care provider's effort to include me in decisions
4.8
Care provider's concern for questions & worries
4.8
Care provider's explanation of condition/problem
4.8
Wait time at clinic
3.6
Care provider's friendliness and courtesy
4.8

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

December 10, 2015

Dr. Deiniger is and amazing doctor I would always recommend him

December 01, 2015

Dr. Deininger is the absolute best!

November 19, 2015

I really love Doctor Deniniger and Doctor Patal was also very nice I just wish they had been a little more prompt in keeping their apt times with me

October 23, 2015

The P A was very good about all things he wanted to know in fact more questions than I expected,also Dr Deininger was also more concerned that I was following all directions that were given to me it was a very pleasing experience and I felt good about their concern for me it was a much needed feeling that helped my fears.

October 20, 2015

Dr. Deininger is awesome! And so are the individuals that worked with him on Monday, October 12.

September 25, 2015

Dr. D is awesome. We have been through some challenging times with how my myeloma has decided to behave. Dr. D has been very thorough in his explain of where we need to go (alway including me in the decision-making process) and moving aggressively on thid disease. His person commitment to keeping me in the loop goes well above the call of duty - including a Friday night phone call from when he was at a social, when he received by results he immediatly called me from that social with positive news. That is the type of relationship that builds / sustains trust and confidence in each other. I am very lucky to have Dr. D as my care provider.

August 28, 2015

we really love having Dr. Deininger as a doctor

August 28, 2015

ALLWAYS recomend Huntsman Hospital to friends .

April 10, 2015

We really appreciate everyone at Huntsman

March 22, 2015

In my opinion, I am lucky to receive care at Huntsman.I have a lot of faith in the medical staff here.

March 20, 2015

dr.deineger has wonderful bedside manner and I feel like he truly cares and understands

February 13, 2015

We would highly recommend the Huntsman

January 16, 2015

I would highly recommend Huntsman and Dr. Deininger

January 12, 2015

Dr Deininger is really a wonderful doctor to work with He makes me feel like I am important and he answers all my questions and concerns. I rave to all my friends about him and tell them that if they get leukemia they need to go to him!

December 11, 2014

really feel they care about me and my situation

November 24, 2014

Not one complaint. Myeloma treatment is not a one size fits all - especially in light of all the emerging (and in many instances research results that somewhat contradict each other). it is important the care provider and patient explore this emerging data some the patient can ultimately make the best decision for their body.

October 26, 2014

I always feel like Dr. Deininger is including me in the decision-making process about my treatment plan. I have asked A LOT of questions, and his patience is outstanding. It is very evident Dr. Deininger not only has a passion for his work, but the importance a care provider has in the holistic approach in treating cancer.

October 21, 2014

De.Deininger is AWESOME!

September 25, 2014

Both Dr. Deininger and PA Sri Tantravani are excellent. I love how they explain any aspect I have questions or concerns about. They make me feel like they care and they have time for me.

August 28, 2014

Given the circumstances, it was a very positive experience.

July 06, 2014

Good

July 01, 2014

Dr. Deininger, the fellow, Sri, the nurse practitioner, Renee, the nurse, Mary, all the lab technicians, MA's, and administrative assistants could not have higher standards.

June 28, 2014

I couldn't be happier with both Dr. Deininger and his assistant Sri Tantravanhi. They certainly make me feel like they have time to answer questions and explain things to me, and they don't talk down to me by over-simplifying. They both have great client relationship skills.

June 19, 2014

Dr. Deininger is an incredible doctor. It is sometimes difficult to explain your symptoms to him using language you both understand, but you finally get there. I can accept this due to his expertise.

June 19, 2014

I would have liked to spend a bit more time with the Doct, but I guess that will happen once test results are in.

June 19, 2014

dr. is very knowledgable and caring. very kind and understanding.

June 16, 2014

Only concern was wait time

June 10, 2014

This is the struggle I am having. I have been throwing around the idea of seeking treatment elsewhere. But I truly believe in Dr.Deineger and his abilities. He is a fabulous doctor, its the fact that I see him so little and the people I am left to deal with if I have questions are not good. The fact that I have to bring these concerns up in a facility that is world renowned and has such a honest, caring philosophy behind it is saddening.

June 09, 2014

Dr. Deininger and all of his staff I would highly recommend as this is a very stressful time in life and they do everything they can to make it as good as possible.

May 15, 2014

I'm so thrilled with my new doctor and his assistant. It's clear they both explain things in as much detail as I need. I love his style (both of them actually). I feel my relationship with them will be very good.

May 05, 2014

We love having Dr. Deininger as a Doctor he makes us feel very comfortable

April 30, 2014

She did have problems getting me numbed up so this procedure was the most painful of all the aspirations I have had. No necessarily putting all the blame on the PA.

April 30, 2014

I mentioned the bad experience I had with this bone marrow aspiration. The doctor shook his head and said yea you had a painful experience I know. This seemed rude to me. All I needed was for my doctor to acknowledge it and act a little concerned that I was still in pain. It makes me think they should experience an aspiration so they can relate to the patients more. He did give me good news for which I was very grateful.

April 24, 2014

I spoke with a fellow and then later the doctor. They were both very knowledgable. Their explanations were crystal clear. They also calmed my fears about my prognosis.

March 27, 2014

I would recommend Dr. Deininger to anyone but not the wait time required to see him.

March 10, 2014

I am hard of hearing & had to rely on my husband in some instances. The Doctor is very soft spoken.

March 04, 2014

very impressed with Dr. Deininger and confident with him as my physician

February 24, 2014

I have the utmost trust in Dr. Deininger and his staff

January 31, 2014

I'm not sure what to expect for my upcoming visit. it's for a bone marrow biopsy. and I'm nervous. I would like to know what I need to do to prepare. I left the exam room with the possibility of having the procedure done that day, but after waiting for blood results I found out that I had to schedule it for another appointment. I made the new appointment and left, not knowing anything about what to expect.

January 16, 2014

I like and prefer them.

January 01, 2014

The care of all who participated in the segments of the appointment was excellent -- caring and considerate and professional. The excellent medical service performed by the doctor for completion of the Bone Marrow Biopsy was particularly appreciated, helping to make the experience only of modest discomfort. Overall, the day's activity with the various aspects (components) of the appointment/visit were quite positive.

December 27, 2013

I could not be more pleased with the care I received from Dr. Deininger.

December 19, 2013

the PA asked what I was having done and who ordered the procedure as she did not have that info- instills a lot of confidence in you! The MD did explain the procedure well

December 14, 2013

I am confident with Huntsman and I think I get the best care possible

December 02, 2013

The Dr. spent time describing my options and how the treatments would affect me. He answered all my family's questions.

November 25, 2013

Dr Deininger is very soft spoken so he was very calming

November 20, 2013

The care takers are very good.they are skilled and experienced.

October 19, 2013

I always feel as though my health problems are a real concern to those who help me at the Huntsman Center

October 04, 2013

They all know their job very well and take every care of the patient.

October 04, 2013

no bad ones

July 24, 2013

Dr. D is an exceptional doc! I am so blessed to have found him!!!

July 17, 2013

They were caring and knowledgeable and friendly.

March 04, 2013

i woud recommend the provider, but NOT in this clinic.

February 04, 2013

The main Dr was great! The ast not so much I feel he didn't really listen & kept asking me the same questions over & over

January 01, 2013

I was so impressed with the time the doctor and intern. spent with me explaining my condition. They genuinely cared for me. This was the first time I had met my doctor and I now completely trust him. I feel he cares about me and my health.

November 30, 2012

I wasn't sure what to expect coming in (though I had spoken with someone who had been there). I was impressed with how thorough everyone was. No one seemed rushed or in a hurry to leave. I was grateful for the information and left feeling much better than when I arrived (about my care going forward).

November 23, 2012

All the doctors I've seen obviously talk with each other and all are on the same page. They are willing to discuss anything and everything on the patients terms. I like and trust all the doctors.

November 18, 2012

The attending MD fellow was very thorough in his examination and explanations as well as the primary physician. They clearly listened to my concerns and were willing to work towards approaches to my medical condition.

October 22, 2012

very pleased with doctor. Due to may hearing difficulties and docotr's softspokeness, I hade to keep asking him to repeat himself. Sorry

October 19, 2012

Dr. Deininger was fabulous! I had such a good experience with him & was so glad that I was able to get an appointment with him. I have lots of confidence with him & am looking forward to the next visit.

October 08, 2012

Excellent care and service thank you

September 28, 2012

Dr Deininger is very easy to talk to and he does explain in terms that are very understandable to me. He makes a person feel as if he is in no hurry and will set there for as long as it takes to answer all my questions. My family and I are very impressed with him.

July 20, 2012

Dr Deininger will be making recommendations after reviewing all my records and biopsy slides. I am confident that the advice for treatment will be well-thought out because of the time he is taking to review everything before making a final decision for t

April 03, 2012

The care providers were great.

Academic Profile

Research Interests

  • Chronic Myeloid Leukemia
  • Myeloproliferative Neoplasms
  • Leukemia Drug Resistance
  • Autologous Stem Cell Transplantation

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Oncological Sciences - Adjunct Professor
Academic Divisions Hematology/BMT
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 581-6363 Huntsman Cancer Institute
Hematology
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Michael Deininger is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He is an HCI investigator and member of the Experimental Therapeutics program. He has extensive experience treating patients with blood cancers, including chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia.

Dr. Deininger received his MD from the University of Würzburg Medical School, Germany, in 1990. Throughout his studies he was funded by the prestigious German Scholarship Foundation. He subsequently trained in Internal Medicine and Hematology/Oncology. In 1995 he obtained a grant to enroll in the PhD program at Imperial College, London. His thesis work focused on signal transduction and the potential use of imatinib (Gleevec) as molecularly targeted therapy for CML. After returning to Germany he completed a fellowship in stem cell transplantation at the University of Leipzig Medical Center. In 2002 he was recruited to the Division of Hematology and Medical Oncology at Oregon Health & Science University as an Assistant Professor. In 2007 he was promoted to the rank of Associate Professor and became the Head of the Hematologic Malignancies Section at OHSU. In August 2010 Dr. Deininger became the M.M. Wintrobe Professor of Medicine at the University of Utah and was appointed Chief of the Division of Hematology and Hematologic Malignancies. He was also appointed Senior Director for Transdisciplinary Research at Huntsman Cancer Institute.

Dr. Deininger’s scientific focus is leukemia, specifically myeloproliferative neoplasms (MPN) including CML, chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF). As a clinician-scientist with a translational research focus Dr. Deininger is heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance and new molecular therapies in leukemia. Dr. Deininger’s work describing the selective effects of imatinib on CML cells provided the rationale for clinical trials that led to the approval of Gleevec as the first molecularly-based therapy for leukemia. Current work in his lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets and developing more specific signal transduction inhibitors. Dr. Deininger’s work encompasses more than 200 articles in the peer-reviewed literature, including journals like Cancer Cell, Blood, Journal of Clinical Investigation and the New England Journal of Medicine. He has co-authored more than 10 book chapters, with contributions in leading textbooks such as deVita’s Principles of Oncology. He is a regular speaker at major international scientific meetings, such as the American Society of Hematology and the European Hematology Association and a peer reviewer for journals like Nature Genetics and Cancer Cell. His honors include the Alexandra Kefalides Prize for Leukemia Research, membership on the Editorial Board of Blood (the leading journal in Hematology) and Thompson Reuters Highly Cited Researcher award in 2014 and 2015. Dr. Deininger serves as the vice-Chair for NCCN CML panel and is a member of the NCCN MPN panel.

Education

Education History

Type School Degree
Fellowship University of Leipzig, Department of Hematology
Clinical Fellow
Doctoral Training Imperial College London
Ph.D.
Research Fellow Hammersmith Hospital, Department of Haematology
Research Fellow
Residency Institute of Medical Oncology and Haematology, Nürnberg General Hospital
Resident
Internship Katholische Stiftung Marienhospital Aachen
Intern
Professional Medical University of Würzburg
Medicine
M.D.
Doctoral Training University of Regensburg

Publications

Selected Provider Publications

Journal Article

  1. Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW (2016). A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza(R)) in Patients with Chronic Myelomonocytic Leukemia. Leuk Lymphoma, 1-12.
  2. Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, OHare T (2015). Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.LID - 10.1038/leu.2015.318 [doi]. (Epub ahead of print) Leukemia.
  3. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Muller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S (2015). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.LID - blood-2015-08-660977 [pii]. (Epub ahead of print) Blood.
  4. Deininger MW (2015). Molecular monitoring in CML and the prospects for treatment-free remissions. Hematology Am Soc Hematol Educ Program, 2015(1), 257-63.
  5. Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, OHare T, Deininger MW (2015). Age-related mutations and chronic myelomonocytic leukemia.LID - 10.1038/leu.2015.337 [doi]. (Epub ahead of print) Leukemia.
  6. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S (2015). The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood, 126(13), 1551-4.
  7. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, OHare T, Druker BJ (2015). Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A, 112(39), E5381-90.
  8. Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, OHare T, Deininger MW (2015). beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia, 29(12), 2328-37.
  9. Deininger MW (2015). Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book, 35, e381-8.
  10. Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, OHare T, Deininger MW (2015). Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol, 43(7), 537-45.e1-11.
  11. Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA (2015). Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma, 56(7), 1938-48.
  12. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H (2015). Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 100(4), 479-88.
  13. Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, OHare T (2015). Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia, 29(9), 1939-42.
  14. Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, OHare T, Deininger MW, Lim CS (2015). A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia, 29(8), 1668-75.
  15. Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, OHare T, Deininger MW (2015). shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood, 125(11), 1772-81.
  16. Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA (2015). Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance. Nat Med, 21(1), 71-5.
  17. Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, OHare T, Gunning PT, Deininger MW (2015). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 29(3), 586-97.
  18. OBrien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H (2014). Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw, 12(11), 1590-610.
  19. Eiring AM, Deininger MW (2014). Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol, 15(9), 461.
  20. Agarwal AAUID- ORCID httporcidorg0000-0002-8319-6162, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, OHare T, Roberts JM, Druker BJ, Deininger MW (2014). BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood, 124(22), 3260-73.
  21. Tantravahi SK, Salama ME, Deininger MN (2014). Aggressive systemic mastocytosis mimicking lymphoma: description of an unusual presentation and review of the literature on current management strategies. Leuk Lymphoma, 55(12), 2963-6.
  22. Deininger M (2014). The current status of ponatinib in the treatment of chronic myeloid leukemia. Clin Adv Hematol Oncol, 12(5), 329-31.
  23. Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. J Natl Compr Canc Netw, 12(8), 1113-21.
  24. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, OHare T (2014). BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell, 26(3), 428-42.
  25. Jabbour E, Ottmann OG, Deininger M, Hochhaus A (2014). Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica, 99(1), 7-18.
  26. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C (2014). Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 99(2), 292-8.
  27. Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Muller MC, Radich JP, Shah NP (2014). Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res, 38(1), 10-20.
  28. Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ (2014). Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol, 164(2), 223-32.
  29. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013). The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol, 161(4), 508-16.
  30. OBrien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H (2013). Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw, 11(11), 1327-40.
  31. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, OHare T, Druker BJ, Loriaux MM (2013). Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res, 73(1), 285-96.
  32. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, OHare T, Deininger MW (2013). BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood, 121(3), 489-98.
  33. Melkus M, Bennaceur-Griscelli A, Valogne Y, Flamant S, Chomel JC, Sorel N, Bonnet ML, Deininger MW, Mitjavila-Garcia MT, Turhan AG (2013). Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model. Exp Hematol, 41(4), 335-45.e3.
  34. Kurokawa M, Ito T, Yang CS, Zhao C, Macintyre AN, Rizzieri DA, Rathmell JC, Deininger MW, Reya T, Kornbluth S (2013). Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. Proc Natl Acad Sci U S A, 110(6), 2300-5.
  35. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013). Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 31(10), 1285-92.
  36. OHare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ (2013). Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res, 73(11), 3356-70.
  37. Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG (2013). Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol, 71(6), 1599-607.
  38. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW (2013). Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med, 368(19), 1781-90.
  39. Corbin AS, OHare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW (2013). KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res, 73(18), 5775-86.
  40. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013). Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 98(12), 1865-71.
  41. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369(19), 1783-96.
  42. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Muschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS (2012). Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood, 119(24), 5621-31.
  43. Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ (2012). A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood, 120(19), 3898-905.
  44. Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Arnett JL, Santho RA, Agirre X, Perentesis JP, Deininger MW, Zheng Y, Bustelo XR, Williams DA, Cancelas JA (2012). Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival. Blood, 120(4), 800-11.
  45. Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW (2012). Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood, 120(13), 2658-68.
  46. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, OHare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012). Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med, 367(22), 2075-88.
  47. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 366(9), 799-807.
  48. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, OHare T, Druker BJ, Deininger MW (2012). Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia, 26(5), 1140-3.
  49. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA (2011). CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 117(2), 591-4.
  50. Deininger M (2011). Hematology: curing CML with imatinib--a dream come true? Nat Rev Clin Oncol, 8(3), 127-8.
  51. Terry EN, Gann PH, Molokie R, Deininger M, Diamond AM (2011). Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment. Leuk Res, 35(6), 831-3.
  52. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, DEmilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst, 103(7), 553-61.
  53. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011). Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest, 121(1), 396-409.
  54. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, OHare T, Druker BJ (2011). The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res, 71(9), 3189-95.
  55. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, OHare T, Druker BJ, Bagby GC, Deininger MW (2011). TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood, 118(24), 6392-8.
  56. OHare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ (2011). The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood, 118(19), 5250-4.
  57. Woessner DW, Lim CS, Deininger MW (2011). Development of an effective therapy for chronic myelogenous leukemia. Cancer J, 17(6), 477-86.
  58. OHare T, Deininger MW, Eide CA, Clackson T, Druker BJ (2011). Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res, 17(2), 212-21.
  59. Lange T, Deininger MW (2010). Molecular diagnostics in chronic myeloid leukemia. Expert Opin Med Diagn, 4(2), 113-24.
  60. Deininger M (2010). Chronic myelogenous leukemia therapy beyond imatinib. Clin Adv Hematol Oncol, 8(3), 178-80.
  61. Bright SA, Campiani G, Deininger MW, Lawler M, Williams DC, Zisterer DM (2010). Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. Biochem Pharmacol, 80(1), 31-8.
  62. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW (2010). CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 115(25), 5232-40.
  63. Bright SA, McElligott AM, OConnell JW, OConnor L, Carroll P, Campiani G, Deininger MW, Conneally E, Lawler M, Williams DC, Zisterer DM (2010). Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer, 102(10), 1474-82.
  64. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW (2010). BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood, 116(17), 3278-85.
  65. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM (2010). MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res, 70(15), 6233-7.
  66. Seo JH, Wood LJ, Agarwal A, OHare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ (2010). A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res, 70(18), 7325-35.
  67. La Rosee P, Deininger MW (2010). Resistance to imatinib: mutations and beyond. Semin Hematol, 47(4), 335-43.
  68. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, OBrien SG, Melo JV, Lange T, Harrington CA, Deininger MW (2010). A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood, 115(2), 315-25.
  69. Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP (2009). Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia, 23(2), 396-9.
  70. Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW (2009). High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia, 23(2), 406-9.
  71. Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM (2009). High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood, 113(8), 1749-55.
  72. Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, OHare T, Deininger MW, Druker BJ, Loriaux MM (2009). Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia, 23(7), 1345-8.
  73. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, OHare T, Heinrich MC, Druker BJ (2009). RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A, 106(21), 8695-700.
  74. Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-Gonzalez L, Esparis-Ogando A, del Peso Ovalle L, Bellon-Echeverria I, de la Cruz-Morcillo MA, Galan Moya EM, Moreno Gimeno I, Gomez JC, Deininger MW, Pandiella A, Sanchez Prieto R (2009). ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. PLoS One, 4(7), e6124.
  75. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW (2009). Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood, 114(13), 2598-605.
  76. Snead JL, OHare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW (2009). Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood, 114(16), 3459-63.
  77. Aichberger KJ, Fleischman AG, Deininger MW (2009). Same mutation, different allele. Blood, 114(14), 2853-4.
  78. Johnson KJ, Griswold IJ, OHare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ (2009). A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS One, 4(10), e7439.
  79. OHare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009). AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16(5), 401-12.
  80. Mauro MJ, Deininger MW (2009). Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol, 22(3), 409-29.
  81. Larson RA, Druker BJ, Guilhot F, OBrien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y, IRIS International Randomized Interferon vs STI571 Study Group (2008). Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 111(8), 4022-4028.
  82. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Muller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM (2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 22(6), 1200-6.
  83. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol, 26(19), 3204-12.
  84. Pelz-Ackermann O, Cross M, Pfeifer H, Deininger M, Wang SY, Al-Ali HK, Niederwieser D, Lange T (2008). Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia, 22(12), 2288-91.
  85. Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J, Deininger MW, Church G, Zhu J, Daley GQ (2008). Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene, 27(6), 775-82.
  86. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, OHare T, Heinrich MC, Deininger MW, Druker BJ (2008). RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood, 111(4), 2238-45.
  87. Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ (2008). High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood, 111(9), 4788-96.
  88. Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD (2008). An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn, 10(2), 177-80.
  89. Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW (2008). Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia, 22(6), 1184-90.
  90. OHare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW (2008). SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A, 105(14), 5507-12.
  91. Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW (2008). An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia, 22(12), 2269-72.
  92. MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW (2008). Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia, 22(7), 1354-60.
  93. Agarwal A, Bumm TG, Corbin AS, OHare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW (2008). Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood, 112(5), 1960-70.
  94. Bao F, Polk P, Nordberg ML, Veillon DM, Sun A, Deininger M, Murray D, Andersson BS, Munker R (2007). Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res, 31(11), 1511-20.
  95. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW (2007). Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia, 21(3), 489-93.
  96. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F (2007). The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer, 110(7), 1509-19.
  97. Blasdel C, Egorin MJ, Lagattuta TF, Druker BJ, Deininger MW (2007). Therapeutic drug monitoring in CML patients on imatinib. Blood, 110(5), 1699-701; author reply 1701.
  98. Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW (2007). A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res, 13(20), 6136-43.
  99. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG (2007). Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell, 12(6), 501-13.
  100. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boque C, Faber E, Nagler A, Pogliani E, Russell N, Volin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D (2006). The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 91(4), 452-9.
  101. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC (2006). Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res, 66(1), 473-81.
  102. Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ (2006). Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res, 30(9), 1097-104.
  103. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ (2006). BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood, 107(11), 4250-6.
  104. Demehri S, Corbin A, Loriaux M, Druker BJ, Deininger MW (2006). Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Exp Hematol, 34(3), 284-8.
  105. Bradeen HA, Eide CA, OHare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006). Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood, 108(7), 2332-8.
  106. Walters DK, Mercher T, Gu TL, OHare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ (2006). Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10(1), 65-75.
  107. Griswold IJ, MacPartlin M, Bumm T, Goss VL, OHare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW (2006). Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol, 26(16), 6082-93.
  108. La Rosee P, Jia T, Demehri S, Hartel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW (2006). Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin Cancer Res, 12(21), 6540-6.
  109. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW (2006). Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res, 66(23), 11156-65.
  110. Druker BJ, Guilhot F, OBrien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355(23), 2408-17.
  111. Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P (2005). Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J, 19(8), 960-2.
  112. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P (2005). Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res, 65(20), 9436-44.
  113. Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ (2005). RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood, 105(7), 2952-4.
  114. Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T, Branford S, Lim LC, Kegel T, Martinelli G, Hochhaus A, Druker BJ, Deininger MW (2005). e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia, 19(4), 681-4.
  115. Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW (2005). In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood, 106(1), 227-34.
  116. Crossman LC, Mori M, Hsieh YC, Lange T, Paschka P, Harrington CA, Krohn K, Niederwieser DW, Hehlmann R, Hochhaus A, Druker BJ, Deininger MW (2005). In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica, 90(4), 459-64.
  117. Lange T, Bumm T, Mueller M, Otto S, Al-Ali HK, Grommisch L, Musiol S, Franke C, Krahl R, Niederwieser D, Deininger MW (2005). Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia, 19(7), 1262-5.
  118. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW (2005). High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood, 106(6), 2128-37.
  119. OHare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ (2005). In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65(11), 4500-5.
  120. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE (2005). hOCT 1 and resistance to imatinib. Blood, 106(3), 1133-4; author reply 1134.
  121. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW (2005). The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106(10), 3377-9.
  122. Crossman LC, OHare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, OBrien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW (2005). A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia, 19(11), 1859-62.
  123. Chuah C, Barnes DJ, Kwok M, Corbin A, Deininger MW, Druker BJ, Melo JV (2005). Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia, 19(11), 1896-904.
  124. OHare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ (2005). Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res, 11(19 Pt 1), 6987-93.
  125. Lange T, Park B, Willis SG, Deininger MW (2005). BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle, 4(12), 1761-6.
  126. Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R, Poenisch W, Uharek L, Leiblein S, Gentilini C, Petersdorf E, Storb RF, Niederwieser D (2004). BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia, 18(9), 1468-75.
  127. La Rosee P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ (2004). In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood, 103(1), 208-15.
  128. Gaston I, Johnson KJ, Oda T, Bhat A, Reis M, Langdon W, Shen L, Deininger MW, Druker BJ (2004). Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. Exp Hematol, 32(1), 113-21.
  129. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C, Niederwieser D, Druker BJ, Deininger MW (2004). High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J, 5(1), 55-60.
  130. Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Kohler T, Krahl R, Niederwieser D, Deininger MW (2004). Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica, 89(1), 49-57.
  131. Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC (2004). Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia, 18(4), 864-71.
  132. Mauro MJ, Loriaux M, Deininger MW (2004). Ph-positive and -negative myeloproliferative syndromes may co-exist. Leukemia, 18(7), 1305-7.
  133. Griswold IJ, Shen LJ, La Rosee P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW (2004). Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 104(9), 2912-8.
  134. OHare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ (2004). Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood, 104(8), 2532-9.
  135. Melo JV, Deininger MW (2004). Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Hematol Oncol Clin North Am, 18(3), 545-68, vii-viii.
  136. Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW (2004). Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood, 104(12), 3754-7.
  137. Grossmann AH, Kolibaba KS, Willis SG, Corbin AS, Langdon WS, Deininger MW, Druker BJ (2004). Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl. FEBS Lett, 577(3), 555-62.
  138. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Ponisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF (2003). Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 101(4), 1620-9.
  139. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T (2003). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 17(9), 1707-12.
  140. Wiedmann M, Kreth F, Feisthammel J, Deininger M, Mossner J, Caca K (2003). Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? Anticancer Drugs, 14(9), 751-60.
  141. La Rosee P, Shen L, Stoffregen EP, Deininger M, Druker BJ (2003). No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol J, 4(6), 413-9.
  142. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW (2003). High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood, 101(6), 2152-5.
  143. Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW (2003). Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood, 101(5), 1941-9.
  144. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW (2003). Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, 101(11), 4611-4.
  145. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW (2003). Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood, 102(6), 2205-12.
  146. Rumpel M, Friedrich T, Deininger MW (2003). Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase. Blood, 101(11), 4641-3.
  147. Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MW (2003). FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia, 17(10), 1925-9.
  148. Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, Konig H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A (2003). Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 17(12), 2392-400.
  149. Lange T, Niederwieser DW, Deininger MW (2003). Residual disease in chronic myeloid leukemia after induction of molecular remission. N Engl J Med, 349(15), 1483-4.
  150. Tipping AJ, Deininger MW, Goldman JM, Melo JV (2003). Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol, 31(11), 1073-80.
  151. Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ (2003). c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene, 22(55), 8852-60.
  152. Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, Campbell L, Byrne J, Pinto E, Brizard A, Niedermeiser D, Nacheva EP, Guilhot F, Deininger M, Green AR (2002). Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood, 99(12), 4547-53.
  153. Kohler T, Schill C, Deininger MW, Krahl R, Borchert S, Hasenclever D, Leiblein S, Wagner O, Niederwieser D (2002). High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia, 16(1), 22-9.
  154. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002). Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99(6), 1928-37.
  155. Reid AG, Huntly BJ, Hennig E, Niederwieser D, Campbell LJ, Bown N, Telford N, Walker H, Grace CD, Deininger MW, Green AR, Nacheva EP (2002). Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia. Blood, 99(6), 2274-5.
  156. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, OBrien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99(10), 3530-9.
  157. Al-Ali HK, Leiblein S, Kovacs I, Hennig E, Niederwieser D, Deininger M (2002). CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. Blood, 100(3), 1092-3.
  158. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, OBrien SG (2002). A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100(6), 1965-71.
  159. Muller C, Hennig E, Franke C, Krahl R, Leiblein S, Niederwieser D, Deininger MW (2002). The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients. Cancer Genet Cytogenet, 136(2), 149-50.
  160. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ (2002). Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res, 62(24), 7149-53.
  161. Deininger M, Ponisch W, Krahl R, Leiblein S, Edel E, Lange T, Fiedler F, Freund M, Franke A, Pasold R, von Grunhagen U, Herold M, Dolken G, Hoffmann FA, Uhle R, Schultze W, Steglich J, Schwarzer A, Richter P, Winkelmann C, Kettner E, Dachselt K, Subert R, Schwalbe E, Doepper J, Helbig W, Niederwieser D (2001). Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. Bone Marrow Transplant, 27(11), 1125-32.
  162. Deininger MW, Vieira SA, Parada Y, Banerji L, Lam EW, Peters G, Mahon FX, Kohler T, Goldman JM, Melo JV (2001). Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res, 61(21), 8005-13.
  163. Vieira SA, Deininger MW, Sorour A, Sinclair P, Foroni L, Goldman JM, Melo JV (2001). Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer, 32(4), 353-63.
  164. Deininger M, Lehmann T, Krahl R, Hennig E, Muller C, Niederwieser D (2000). No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia. Blood, 96(2), 779-80.
  165. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV (2000). BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res, 60(7), 2049-55.
  166. Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY (2000). The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol, 28(5), 551-7.
  167. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96(3), 1070-9.
  168. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998). The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood, 92(9), 3362-7.
  169. Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, Melo JV (1998). Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res, 58(3), 421-5.
  170. Gora-Tybor J, Deininger MW, Goldman JM, Melo JV (1998). The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. Br J Haematol, 103(3), 716-20.
  171. Deininger MW, Goldman JM, Lydon N, Melo JV (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90(9), 3691-8.

Review

  1. Moslehi JJ, Deininger M (2015). Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. [Review]. J Clin Oncol, 33(35), 4210-8.
  2. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. [Review]. Blood, 122(6), 872-84.
  3. OHare T, Zabriskie MS, Eiring AM, Deininger MW (2012). Pushing the limits of targeted therapy in chronic myeloid leukaemia. [Review]. Nat Rev Cancer, 12(8), 513-26.
  4. Shami PJ, Deininger M (2012). Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. [Review]. Leukemia, 26(2), 214-24.
  5. Deininger MW, Manley P (2012). What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML? [Review]. Leuk Res, 36(3), 253-61.
  6. Jabbour E, Deininger M, Hochhaus A (2011). Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. [Review]. Leukemia, 25(2), 201-10.
  7. Mitchell B, Deininger M (2011). Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia. [Review]. Leuk Lymphoma, 52 Suppl 1, 4-11.
  8. Eiring AM, Khorashad JS, Morley K, Deininger MW (2011). Advances in the treatment of chronic myeloid leukemia. [Review]. BMC Med, 9, 99.
  9. Khorashad JS, Deininger MW (2011). Selection of therapy: rational decisions based on molecular events. [Review]. Hematol Oncol Clin North Am, 25(5), 1009-23, vi.
  10. Traer E, Deininger MW (2010). How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. [Review]. Clin Lymphoma Myeloma Leuk, 10 Suppl 1, S20-6.
  11. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009). Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. [Review]. J Clin Oncol, 27(35), 6041-51.
  12. Valent P, Deininger M (2008). Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. [Review]. Leuk Lymphoma, 49(4), 604-9.
  13. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J (2008). Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. [Review]. Semin Oncol, 35(1 Suppl 1), S1-17; quiz S18-20.
  14. Deininger M (2008). Resistance and relapse with imatinib in CML: causes and consequences. [Review]. J Natl Compr Canc Netw, 6 Suppl 2, S11-S21.
  15. OHare T, Eide CA, Deininger MW (2008). New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. [Review]. Expert Opin Investig Drugs, 17(6), 865-78.
  16. Deininger MW (2008). Nilotinib. [Review]. Clin Cancer Res, 14(13), 4027-31.
  17. Deininger MW (2008). Chronic myeloid leukemia: an historical perspective. [Review]. Hematology Am Soc Hematol Educ Program, 418.
  18. Deininger MW (2008). Milestones and monitoring in patients with CML treated with imatinib. [Review]. Hematology Am Soc Hematol Educ Program, 419-26.
  19. OHare T, Deininger MW (2008). Toward a cure for chronic myeloid leukemia. [Review]. Clin Cancer Res, 14(24), 7971-4.
  20. Snead JL, OHare T, Eide CA, Deininger MW (2008). New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided? [Review]. Clin Lymphoma Myeloma, 8 Suppl 3, S107-17.
  21. Deininger MW (2007). Optimizing therapy of chronic myeloid leukemia. [Review]. Exp Hematol, 35(4 Suppl 1), 144-54.
  22. OHare T, Eide CA, Deininger MW (2007). Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. [Review]. Clin Lymphoma Myeloma, 7 Suppl 3, S120-30.
  23. OHare T, Eide CA, Deininger MW (2007). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. [Review]. Blood, 110(7), 2242-9.
  24. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. [Review]. Blood, 108(1), 28-37.
  25. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006). Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. [Review]. Blood, 108(6), 1809-20.
  26. Mauro MJ, Deininger MW (2006). Chronic myeloid leukemia in 2006: a perspective. [Review]. Haematologica, 91(2), 152.
  27. Deininger M, Buchdunger E, Druker BJ (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. [Review]. Blood, 105(7), 2640-53.
  28. Deininger M (2005). Resistance to imatinib: mechanisms and management. [Review]. J Natl Compr Canc Netw, 3(6), 757-68.
  29. Deininger MW (2005). Management of early stage disease. [Review]. Hematology Am Soc Hematol Educ Program, 174-82.
  30. Silver RT, Bennett JM, Deininger M, Feldman E, Rafii S, Silverstein RL, Solberg LA, Spivak JL (2004). The second international congress on myeloproliferative and myelodysplastic syndromes. [Review]. Leuk Res, 28(9), 979-85.
  31. Loriaux M, Deininger M (2004). Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. [Review]. Leuk Lymphoma, 45(11), 2197-203.
  32. Deininger MW (2004). Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. [Review]. J Cancer Res Clin Oncol, 130(2), 59-72.
  33. Deininger MW, OBrien SG, Ford JM, Druker BJ (2003). Practical management of patients with chronic myeloid leukemia receiving imatinib. [Review]. J Clin Oncol, 21(8), 1637-47.
  34. OBrien SG, Deininger MW (2003). Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. [Review]. Semin Hematol, 40(2 Suppl 2), 26-30.
  35. Deininger MW (2003). Cytogenetic studies in patients on imatinib. [Review]. Semin Hematol, 40(2 Suppl 2), 50-5.
  36. Deininger MW, Druker BJ (2003). Specific targeted therapy of chronic myelogenous leukemia with imatinib. [Review]. Pharmacol Rev, 55(3), 401-23.
  37. Deininger M, Niederwieser D (2002). [Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases]. [Review]. Med Klin (Munich), 97 Suppl 1, 1.
  38. Deininger MW, Goldman JM, Melo JV (2000). The molecular biology of chronic myeloid leukemia. [Review]. Blood, 96(10), 3343-56.
  39. Deininger MW, Goldman JM (1998). Chronic myeloid leukemia. [Review]. Curr Opin Hematol, 5(4), 302-8.

Book Chapter

  1. Deininger MW, John P Greer, Daniel A Arber, Bertil Glader, Alan F List, Robert T Means Jr, Frizos Paraskevas, George M Rodgers (2013). Chronic Myeloid Leukemia. In Wintrobe’s Clinical Hematology (13th). Wolters Kluwer.
  2. Shenoy S, Deininger MW (2012). Myeloproliferative and Myelodysplastic Disorders in Children, Adolescents and Young Adults. In Cairo MS and Perkins SL (Eds.). (Eds.), Hematological Malignancies in Children, Adolescents and Young Adults. World Scientific Publishing.
  3. Agarwal A, Byrd J, Deininger MW (2012). Chronic Leukemias. In DeVita V, Lawrence TS, Rosenberg SA (Eds.). (Eds.), Cancer: Principles & Practice of Oncology: Primer of the Molecular Biology. Wolters Kluwer.
  4. OHare T, Eide CA, Deininger MW (2009). A new generation of drugs in cancer treatment: molecularly targeted therapies. In Stein G, Pardee A (Eds.), The Biology and Treatment of Cancer: Understanding Cancer (pp. 193-222). Hoboken, NJ: John Wiley & Sons, Inc.
  5. Deininger MW, Cortes J Eds (2008). Chronic myeloid leukemia. CRC Press.
  6. La Rosee P, Deininger MW (2008). Cytogenetics and Molecular Biology of Chronic Myeloid Leukaemia. In Mughal T, Goldman JM (Eds.), Chronic Myeloproliferative Disorders (pp. 17-43). Informa Healthcare.
  7. Deininger MW (2007). Tyrosine Kinase Inhibitors. In Gewirtz E (Ed.), Apoptosis and Senescence in Cancer. McGraw Hill.
  8. Deininger MW (2007). Chronic myeloid leukemia: molecular biology, pathology and cytogenetics. In Sekeres MA, Kalaycio ME, Bolwell BJ (Eds.), Clinical Malignant Hematology. McGraw-Hill.
  9. Deininger MW, Druker BJ (2007). Drug Therapy of Chronic Myeloid Leukaemia. In Fojo T (Ed.), Chemotherapy Sourcebook. Lippincot.
  10. Deininger MW (2006). BCR-ABL as a molecular target. In Deininger MW, Cortes J (Eds.), Chronic Myeloid Leukemia (pp. 1-12). New York and Oxford: Informa.
  11. Deininger MW (2006). Signal Transduction Inhibitors in Chronic Myeloid Leukemia. In Melo, Goldman (Eds.), Myeloproliferative Disorders (pp. 75-109). Berlin&Heidelberg: Springer.
  12. Deininger MW (2004). Clinical Applications. In Stein G, Pardee A (Eds.), Cell cycle and Growth control: Biomolecular Regulation and Cancer (pp. 660-707). New York: Wiley&Sons.
  13. Deininger MW (2002). Grundlagen der Therapie mit Imatinib Mesilat. In Fischer T (Ed.), Der Signalhemmer Imatinib Mesilat (pp. 12-29). Bremen: Uni-Med Verlag.

Case Report

  1. Ernst T, Score J, Deininger M, Hidalgo-Curtis C, Lackie P, Ershler WB, Goldman JM, Cross NC, Grand F (2011). Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br J Haematol, 153(1), 43-6.

Editorial

  1. Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, OHare T, Goldman JM (2013). What challenges remain in chronic myeloid leukemia research? Haematologica, 98(8), 1168-72.
  2. Khorashad JS, Deininger MW, OHare T (2013). New concepts for CML clonality. Oncotarget, 4(1), 7-8.
  3. OHare T, Eide CA, Deininger MW (2008). Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia. J Natl Cancer Inst, 100(13), 908-9.
  4. OHare T, Walters DK, Deininger MW, Druker BJ (2005). AMN107: tightening the grip of imatinib. Cancer Cell, 7(2), 117-9.
  5. Deininger MW, Holyoake TL (2005). Can we afford to let sleeping dogs lie? Blood, 105(5), 1840-1.
  6. Deininger M (2004). Src kinases in Ph+ lymphoblastic leukemia. Nat Genet, 36(5), 440-1.
  7. Deininger MW, Druker BJ (2004). SRCircumventing imatinib resistance. Cancer Cell, 6(2), 108-10.

Letter

  1. Tantravahi SK, Schumacher J, Burt RW, Kelley TW, Deininger MW (2014). Systemic mastocytosis in a patient with Cowden syndrome [Letter to the editor]. Am J Hematol, 89(12), 1154.
  2. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE (2013). Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study [Letter to the editor]. Br J Haematol, 162(4), 548-52.
  3. Demehri S, OHare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW (2010). The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis [Letter to the editor]. Leukemia, 24(1), 226-9.

Abstract

  1. Andersen EF, Salama ME, Sederberg MC, Toydemir RM, Kovacsovics TJ, Parker CJ, Rodgers GM, Shami PJ, Deininger MW, South ST (2015). Evaluating the Clinical Utility of Peripheral Blood Samples for Molecular Evaluation of MDS by SNP-A [Abstract]. Leukemia Research, 39(S1), S72.
  2. Agarwal A, Mackenzie R, LaTocha D, Vasudevan K, Firpo E, Loriaux M, Nakayama K, Druker BJ, Roberts JM, Deininger M (Nov 2009). The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 3276.
  3. McWeeney S, Yochum G, Pemberton LC, Loriaux M, Vartanian K, Willis SG, Wilmot B, Turpaz Y, Pillai R, Mac partlin M, Snead J, Druker BJ, OBrien SG, Melo JV, Lange T, Harrington C, Deininger M (Nov 2009). A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 508.
  4. Aichberger KJ, Fleischman AG, Doratotaj S, Bumm TGP, Silver RT, Deloughery TG, Pahl HL, Druker BJ, Burns CJ, Deininger M (Nov 2009). Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2917.
  5. Mackenzie R, Snead J, VanDyke J, Deininger M (Nov 2009). Defining Extrinsic Survival Pathways in CML Progenitor Cells (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 941.
  6. Khoury HJ, Mauro MJ, Matloub Y, Chen T, Bahceci E, Deininger M (Nov 2009). 9. Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 1128.
  7. Deininger M, OBrien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ (Nov 2009). International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 1126.
  8. Deininger M, Mahon FX, Guilhot F, Saglio G, le Coutre P, Nagler A, DEmilio A, Stagno F, Morra E, Piccin A, Assouline SE, Abruzzese E, Santini V, Pane F, Giraldo P, Antolini L, Valsecchi MG, Gambacorti-Passerini C (Nov 2009). Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 1108.
  9. Tyner JW, Loriaux M, Willis SG, Chang BH, Bicocca VT, Oh ST, Hollink I, Segers S, DenBoer ML, van den Heuvel-Eibrink MM, Zwaan CM, Gotlib JR, Deininger M, Druker BJ (Nov 2009). RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 3978.
  10. Bhatia R, Snyder DS, Lin A, Arceo J, Seymour L, Deininger M, Radich J, Blanchard S, Forman S (Nov 2009). A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2194.
  11. Lunghi P, Mazzera L, Corradi A, Cantoni AM, Jottini S, Lombardi G, Ricca M, Arienti D, Rizzoli V, Deininger MW, Bonati A (Nov 2009). Arsenic Trioxide (ATO) Interacts Synergistically with MEK Inhibitors to Induce Apoptosis in STI571-Resistant Bcr-Abl Mutants (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2177.
  12. Tyner JW, Fletcher L, Yang W, Oh ST, Gotlib JR, Deininger MW, Druker BJ, Loriaux M (Nov 2009). Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 708.
  13. Cortes J, Talpaz M, Deininger M, Shah N, Flinn IW, Mauro MJ, OHare T, Spinos N, Hu S, Berk L, Narasimhan N, Rivera VM, Clackson T, Haluska F, Kantarjian HM (Nov 2009). A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 643.
  14. Kim DW, Antolini L, Mahon FX, Guilhot F, Deininger M, Saglio G, Nagler A, Rambaldi A, Morra E, Abruzzese E, Di Raimondo F, le Coutre P, Monroy RH, Durosinmi MA, Leeksma O, Pane F, Miglietta S, Kweon I, Reiffers J, Valsecchi MG, Gambacorti-Passerini C (Nov 2009). Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2199.
  15. Bumm TGP, Tyner JW, Deininger J, Loriaux M, VanDyke J, Druker BJ, Burns CJ, Fantino E, Deininger MW (Nov 2008). Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 856.
  16. Tyner JW, Loriaux M, Willis SG, Chang B, Bicocca VT, Oh S, Hollink I, Segers S, den Boer ML, Zwaan CM, Gotlib JR, Deininger MW, Druker BJ (Nov 2008). RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 758.
  17. Deininger MW, Mauro MJ, Matloub Y, Sinha R, Ploughman L, Liu D, Radich J (Nov 2008). Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 3236.
  18. Tyner JW, Erickson H, Oh S, Gotlib JR, Deininger MW, Druker BJ, Loriaux M (Nov 2008). Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 2519.
  19. Corbin AS, OHare T, Druker BJ, Deininger MW (Nov 2008). Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 190.
  20. OHare T, Eide CA, Adrian LT, Rivera VM, Shakespeare WC, Clackson T, Deininger MW, Druker BJ (Nov 2008). Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 726.
  21. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW (Nov 2008). Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 1108.
  22. Gambacorti-Passerini C, Kim D, Mahon F, Saglio G, Pane F, Guilhot F, Deininger MW, Nagler A, Rambaldi A, Morra E, Antolini L, Kweon I, Reiffers J, Tornaghi L, Valsecchi MG (Nov 2008). Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 1099.
  23. OHare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW (Nov 2007). SGX70393 Inhibits Bcr-AblT315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 535.
  24. Bumm TGP, Newell AH, Oost J, VanDyke J, Olson SB, Druker BJ, Deininger MW (Nov 2007). Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 36.
  25. MacPartlin M, Honigberg LA, Druker BJ, Deininger MW (Nov 2007). Bruton's Tyrosine Kinase (BTK) Is Not Required for BCR-ABL-Mediated Transformation of Hematopoietic Cells (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1015.
  26. McWeeney SK, Pemberton LC, Harrington CA, Druker BJ, Deininger MW (Nov 2007). A Transcriptomal Profile for Predicting Complete Cytogenetic Response (CCR) in Chronic Phase CML Patients Treated with Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1007.
  27. Agarwal A, Eide CA, Harlow A, Tyner JW, Mauro MJ, Corless CL, Heinrich MC, Druker BJ, Deininger MW (Nov 2007). An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1006.
  28. Jeffrey W Tyner, Stephanie Willis, Michael WN Deininger, and Brian J Druker (Nov 2007). RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 208.
  29. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker MJ, Gilliland DG (Nov 2007). Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 208.
  30. Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD (Nov 2007). An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1953.
  31. Mauro MJ, Press RD, Deininger MW, Druker BJ (Nov 2007). BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1945.
  32. Loriaux M, Levine R, Tyner J, Frohling S, Scholl C, Stoffregen E, Wernig G, Erickson H, Eide C, Berger R, Bernard O, Griffin J, Stone R, Meyerson M, Heinrich M, Deininger M, Gilliland G, Druker B (Nov 2007). High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 886.
  33. Bumm TGP, VanDyke J, Loriaux M, Gendron C, Wood LG, Druker BJ, Deininger MW (Nov 2007). TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 675.
  34. Sherbenou DW, Hantschel OJ, Turaga L, Mag IK, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW (Nov 2007). Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 2936.
  35. Pelz-Ackermann O, Deininger MW, Cross M, Wildenberger K, Krahl R, Wang S, Al-Ali HK, Niederwieser DW, Lange T (Nov 2007). BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 2918.
  36. Pelz-Ackermann O, Deininger MW, Cross M, Kovacs I, Guenther C, Krohn K, Wang S, Al-Ali HK, Niederwieser DW, Lange T (Nov 2006). First Results of a New PCR-Based Approach for a Sensitive and Quantitative Monitoring of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 2191.
  37. Sherbenou DW, Hantschel O, Willis S, Press RD, Druker BJ, Superti-Furga G, Deininger MW (Nov 2006). A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 2188.
  38. Press RD, Willis S, Rempfer C, Mauro MJ, Druker BJ, Deininger MW (Nov 2006). A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 2152.
  39. Nardi V, Raz T, Chao X, Wu CJ, Stone R, Galinsky I, Wadleigh M, Deininger MW, Church G, Zhu J, Daley GQ (Nov 2006). Monitoring Imatinib Resistance with a "Polony" Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML) (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 837.
  40. Agarwal A, Bumm TGP, Corbin A, OHare T, Loriaux M, Willis SG, Deininger J, Druker BJ, Deininger MW (Nov 2006). The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 742.
  41. MacPartlin M, OHare T, Bumm T, Goss V, Lee K, Corbin A, Stoffregen EA, Smith C, Johnson K, Moseson E, Griswold I, Wood L, Polakiewicz R, Druker BJ, Deininger MW (Nov 2006). Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 4796.
  42. OHare T, Eide CA, Tyner JW, Wong MJ, Smith CA, Corbin AS, Buchanan S, Jessen KA, Tang C, Holme K, Burley SK, Deininger MW (Nov 2006). Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393 (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 1373.
  43. Tyner JW, Eide CA, Stoffregen EP, Loriaux M, Willis SG, Gattermann N, Kovacsovics T, Druker BJ, Deininger MW (Nov 2006). Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 3606.

Clinical Trials

Video & News

Video